Vascular Complications and Management Strategies in COVID-19: A Comprehensive Review

A comprehensive review, published in the Canadian Journal of Cardiology, sheds light on the vascular complications associated with COVID-19 and the evolving management strategies.

Here’s a summary of its key findings:

  1. Endothelial Dysfunction and COVID-19: The review highlights that endothelial dysfunction plays a pivotal role in the pathogenesis and clinical course of COVID-19. The virus affects respiratory function and can lead to systemic inflammation, endothelial dysfunction, and coagulopathy, predisposing individuals to hematologic and vascular complications​​.
  2. Triggering Coagulation Pathways: Endothelial injury in COVID-19 can activate coagulation pathways, potentially leading to disseminated intravascular coagulation. This process involves platelet recruitment, cytokine release, and the expression of adhesion proteins, which exacerbate the thromboinflammatory process. Elevated levels of inflammatory markers and hematological changes, such as thrombocytopenia and high D-dimer levels, have been linked to increased mortality and adverse outcomes​​.
  3. Risk of Thrombotic Events: Patients with COVID-19 are at high risk for deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and ischemic stroke. Notably, this risk persists even after hospital discharge, indicating long-term vascular implications of the infection​​
  4. Increased Risk of Venous Thromboembolism (VTE): Studies have shown an elevated risk of VTE, especially in patients with severe COVID-19 and those with additional VTE risk factors. The prevalence of VTE was notably higher in intensive care unit (ICU) patients compared to non-ICU patients​​.
  5. Bleeding Complications: While COVID-19 is primarily associated with hypercoagulability, patients, particularly those receiving anticoagulation therapy, may also face increased risks of bleeding. The causes are multifactorial, including the intensity of anticoagulation therapy and critical illness-related bleeding risks​​.
  6. Anticoagulation Management: Various randomized controlled trials (RCTs) have evaluated anticoagulation in COVID-19 patients. Recommendations include pharmacological thromboprophylaxis for all hospitalized patients unless contraindicated. Empirical therapeutic anticoagulation might be considered for non-critically ill hospitalized patients with high thrombosis risk and low bleeding risk​​.
  7. Future Research and Uncertainties: The review emphasizes the need for further research, particularly in understanding the impact of new viral variants and vaccinations on vascular complications. The long-term management of these complications post-COVID-19 infection remains an area of ongoing investigation​​.

In conclusion, this review underscores the importance of understanding and addressing the vascular complications in COVID-19, highlighting the evolving nature of treatment strategies and the need for continued research in this area.

Read More: https://onlinecjc.ca/article/S0828-282X%2823%2900272-6/fulltext

Leave a comment